Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
I 3282
Austrian Science Fund FWF - Austria
PubMed
29317454
DOI
10.1182/blood-2017-05-786947
PII: S0006-4971(20)32400-9
Knihovny.cz E-resources
- MeSH
- Adenine analogs & derivatives MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell drug therapy enzymology genetics MeSH
- HEK293 Cells MeSH
- Casein Kinase Idelta antagonists & inhibitors genetics metabolism MeSH
- Casein Kinase 1 epsilon antagonists & inhibitors genetics metabolism MeSH
- Drug Delivery Systems MeSH
- Humans MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neoplasm Proteins antagonists & inhibitors genetics metabolism MeSH
- Piperidines MeSH
- Pyrazoles pharmacology MeSH
- Pyrimidines pharmacology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adenine MeSH
- ibrutinib MeSH Browser
- Casein Kinase Idelta MeSH
- Casein Kinase 1 epsilon MeSH
- Neoplasm Proteins MeSH
- PF-670462 MeSH Browser
- Piperidines MeSH
- Pyrazoles MeSH
- Pyrimidines MeSH
Casein kinase 1δ/ε (CK1δ/ε) is a key component of noncanonical Wnt signaling pathways, which were shown previously to drive pathogenesis of chronic lymphocytic leukemia (CLL). In this study, we investigated thoroughly the effects of CK1δ/ε inhibition on the primary CLL cells and analyzed the therapeutic potential in vivo using 2 murine model systems based on the Eµ-TCL1-induced leukemia (syngeneic adoptive transfer model and spontaneous disease development), which resembles closely human CLL. We can demonstrate that the CK1δ/ε inhibitor PF-670462 significantly blocks microenvironmental interactions (chemotaxis, invasion and communication with stromal cells) in primary CLL cells in all major subtypes of CLL. In the mouse models, CK1 inhibition slows down accumulation of leukemic cells in the peripheral blood and spleen and prevents onset of anemia. As a consequence, PF-670462 treatment results in a significantly longer overall survival. Importantly, CK1 inhibition has synergistic effects to the B-cell receptor (BCR) inhibitors such as ibrutinib in vitro and significantly improves ibrutinib effects in vivo. Mice treated with a combination of PF-670462 and ibrutinib show the slowest progression of disease and survive significantly longer compared with ibrutinib-only treatment when the therapy is discontinued. In summary, this preclinical testing of CK1δ/ε inhibitor PF-670462 demonstrates that CK1 may serve as a novel therapeutic target in CLL, acting in synergy with BCR inhibitors. Our work provides evidence that targeting CK1 can represent an alternative or addition to the therapeutic strategies based on BCR signaling and antiapoptotic signaling (BCL-2) inhibition.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Chemistry and Toxicology Veterinary Research Institute Brno Czech Republic
Department of Histology and Embryology Faculty of Medicine Masaryk University Brno Czech Republic
Institute of Biophysics Academy of Sciences of the Czech Republic Brno Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
Institute of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
References provided by Crossref.org
Porcupine inhibition enhances hypertrophic cartilage differentiation
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells
Can We Pharmacologically Target Dishevelled: The Key Signal Transducer in the Wnt Pathways?
Primary Cilia Formation Does Not Rely on WNT/β-Catenin Signaling
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer